Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a Body Mass Index (BMI) \>= 30kg/m\^2
You may not be if
Have ever participated in this study previously, or any other study using exenatide (AC2993/LY2148568) or GLP-1 analogs
Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of study start (this criterion includes drugs that have not received regulatory approval for any indication at the time of study entry)
Diagnosis of diabetes mellitus (other than gestational diabetes), or previous use of anti-diabetic medications for \> 3 months
Have had a change in prescribed lipid-lowering or blood pressure agents within 4 weeks of screening
Used drugs for weight loss (e.g., Xenical \[orlistat\], Meridia \[sibutramine\], Acutrim \[phenylpropanolamine\], Accomplia \[rimonabant\], Alli \[low-dose orlistat\], or other similar over-the-counter weight loss remedies or medications) within 3 months of screening
Are actively participating in, or have participated in a formal weight loss program within the last 3 months
Have a history of chronic use of drugs that directly affect gastrointestinal motility, including, but not limited to Reglan (metoclopramide) and chronic macrolide antibiotics
Have been treated with any anti-diabetic medications within 3 months of screening
Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study start
Have had bariatric surgery
Have had an organ transplant
Clareo Health | A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
